Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism
Key facts
- Who runs it
- Combined military hospital lahore
- Where
- Pakistan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 540 people enrolled
- Started
- 1 Jan 2021
- Ended
- 15 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Drug: Apixaban
- Drug: Rivaroxaban
- Record updated
- 24 August 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- CT pulmonary angiography-confirmed acute PE
- Intraluminal pulmonary arterial filling defect
Who cannot take part
- Previous major bleeding
- Hemophilia or other bleeding disorder
- Active bleeding
- Known platelet disorder
- Creatinine clearance < 30 mL/min
- Pregnancy or lactation
- Indication for therapeutic anticoagulation other than VTE
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective, open-label, randomized controlled trial will compare clinically relevant bleeding during the first three months of treatment with apixaban versus rivaroxaban in adults with acute pulmonary embolism (PE) in a Pakistani cohort. A total of 540 participants will be randomized 1:1 to receive standard acute-treatment regimens of either apixaban or rivaroxaban. The primary outcome will be the composite of major bleeding or clinically relevant non-major (CRNM) bleeding within three months, defined according to International Society on Thrombosis and Haemostasis (ISTH) criteria.
The 2 groups in the trial
- ApixabanTreatment being tested
Participants will receive 10 mg twice daily for 7 days, then 5 mg twice daily for 3 months total
Treatment: Drug: Apixaban
- RivaroxabanExisting treatment, for comparison
Participants will receive 15 mg twice daily for 21 days, then 20 mg once daily for 3 months total
Treatment: Drug: Rivaroxaban
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism: A Single-Center Randomized Controlled Trial in Pakistan
- Record updated
- 24 August 2026